S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
AirSculpt Technologies, Inc. has announced the results of its 2025 annual meeting of stockholders held on May 7, 2025. The Miami Beach, Florida-based company, which operates in the healthcare sector with a market capitalization of $150.48 million, detailed the outcomes of the votes on various matters submitted to its security holders. According to InvestingPro data, the company maintains a healthy gross profit margin of 63.81% despite operating with significant debt obligations.
The company reported that at the close of business on the record date, March 10, 2025, there were 58,570,880 shares of common stock outstanding. These shares were represented at the Annual Meeting, either in person or by proxy. The stock has shown significant volatility, with InvestingPro analysis revealing a notable return of over 13% in the past week, though it remains down more than 70% over the last six months.
During the meeting, two Class I director nominees were elected to serve for a three-year term. Yogi Jashnani received 46,251,831 votes in favor, 149,644 against, and 229 abstentions, with 10,404,553 broker non-votes. Daniel Sollof received 45,453,687 votes in favor, 947,788 against, and 229 abstentions, with 10,404,553 broker non-votes.
Additionally, the appointment of Grant Thornton as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 56,797,131 votes for, 4,191 against, and 4,935 abstentions.
The results indicate a strong support for the elected directors and the appointed auditor, with substantial majorities in each case. The filing did not include any other items that may have been voted upon at the meeting.
This information is based on the company’s recent SEC filing and provides a snapshot of the corporate governance matters addressed during the annual meeting. The company is listed on The Nasdaq Global Market under the trading symbol "AIRS."
In other recent news, AirSculpt Technologies reported its first-quarter financial results for 2025, revealing a 17.3% decline in revenue to $39.4 million compared to the previous year. Despite this drop, the company surpassed earnings expectations with an earnings per share (EPS) of -$0.02, better than the forecasted -$0.0333. The company has also announced strategic workforce reductions and marketing reallocations, which are anticipated to save $3 million annually. AirSculpt Technologies has provided a revenue guidance of $160-170 million for 2025, with an adjusted EBITDA target of $16-18 million. The company does not anticipate significant revenue from its new skin tightening pilot this year. On the analyst front, AirSculpt Technologies’ strategic adjustments and cost-saving measures were highlighted as areas of focus during the earnings call. The company plans to enhance its marketing efficiency and expand financing options to improve case conversion. Analysts from firms such as Nephron Research and Leerink Partners have engaged with the company to understand its strategic priorities and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.